Literature DB >> 9110294

Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues.

P A Humphrey1, R T Vollmer.   

Abstract

Tumor size is a well-established prognosticator for many malignant neoplasms and is a fundamental component of the tumor-node-metastasis staging system. Prostatic tumor size, assessed in radical prostatectomy specimens by means of a variety of techniques, has been shown to be an important prognosticator. Little is known of the comparative capacity of these various methodologic approaches to predict actual tumor volume. We compared two methods for their ability to predict computer-assisted and morphometrically calculated tumor volume in 100 completely-embedded radical prostatectomy specimens. The two methods, visual inspection and grid morphometric analysis, were applied to estimate the percentage surface area of prostatic tissue sections involved by carcinoma. Statistical analysis entailed correlation coefficient calculation and linear regression analysis, including analysis of variance and model creation. Visual inspection and grid morphometric percentage tumor estimates were significantly related to tumor volume, with similar correlation coefficients of r = 0.79 and 0.81, respectively. Model construction revealed a significant relationship of both percentage estimates with tumor volume, with a model F statistic of 192 for the grid ratio and 161 for the visual inspection data. Incorporation of gland size into the model by using the number of blocks of prostatic tissue as a multiplier diminished the variance, and raised the F value to 989 for the grid ratio and 636 for visual inspection. The final model using either estimate of percentage tumor yielded this equation: tumor volume = factor x percentage carcinoma x number of blocks. We conclude that percentage carcinoma estimates by both visual inspection and grid morphometric analysis are highly significant predictors of tumor volume in radical prostatectomy specimens.

Entities:  

Mesh:

Year:  1997        PMID: 9110294

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  22 in total

Review 1.  What is the pathologist saying? Interpretation of the prostate pathology report.

Authors:  Omar Hameed
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

2.  A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer.

Authors:  Claire Murphy; Lawrence True; Funda Vakar-Lopez; Jing Xia; Roman Gulati; Bruce Montgomery; Maria Tretiakova
Journal:  Prostate       Date:  2016-06-08       Impact factor: 4.104

3.  Is statin use associated with prostate cancer aggressiveness?

Authors:  Stacy Loeb; Donghui Kan; Brian T Helfand; Robert B Nadler; William J Catalona
Journal:  BJU Int       Date:  2009-11-03       Impact factor: 5.588

4.  Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer.

Authors:  Se Young Choi; Byung Hoon Chi; Bumjin Lim; Yoon Soo Kyung; Dalsan You; In Gab Jeong; Cheryn Song; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-08       Impact factor: 4.553

5.  The association between tumour density and prostate cancer recurrence following radical prostatectomy.

Authors:  Luke T Lavallée; Rodney H Breau; Mark A Preston; Gayanna Raju; Christopher Morash; Steve Doucette; Ronald G Gerridzen; James Eastham; Ilias Cagiannos
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

6.  Prostate cancer with bladder neck involvement: pathologic findings with application of a new practical method for tumor extent evaluation and recurrence-free survival after radical prostatectomy.

Authors:  Athanase Billis; Leandro L L Freitas; Luis A Magna; Adil B Samara; Ubirajara Ferreira
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

7.  Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.

Authors:  Gustavo F Carvalhal; Saima N Daudi; Donghui Kan; Dana Mondo; Kimberly A Roehl; Stacy Loeb; William J Catalona
Journal:  Urology       Date:  2010-09-16       Impact factor: 2.649

8.  Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.

Authors:  Xiaoke Sun; Zhen Yang; Yu Zhang; Jing He; Feng Wang; Pengxiao Su; Juanli Han; Zhe Song; Yanjiang Fei
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

9.  Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml.

Authors:  Joshua J Meeks; Stacy Loeb; Brian T Helfand; Donghui Kan; Norm D Smith; William J Catalona
Journal:  J Urol       Date:  2009-04-16       Impact factor: 7.450

10.  Prostate cancer risk alleles are associated with prostate cancer volume and prostate size.

Authors:  Daniel Reinhardt; Brian T Helfand; Phillip R Cooper; Kimberly A Roehl; William J Catalona; Stacy Loeb
Journal:  J Urol       Date:  2013-12-15       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.